08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

ATS907: Phase IIa started

Altheos began a 2-stage, single-blind, dose-ranging, U.S. Phase IIa trial of once- or twice-daily ATS907 eye drops for up to 28 days in about 210 patients with primary open-angle glaucoma and/or ocular hypertension. The first...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Financial News

Altheos financial update

Altheos raised an additional $12.5 million in a series A round, bringing the total raised in the round to $32.5 million. Altheos raised $20 million in the round in April 2010. Altheos Inc. , South...
01:19 , Feb 10, 2012 |  BC Extra  |  Financial News

Altheos raises $12.5M, starts glaucoma trial

Altheos Inc. (South San Francisco, Calif.) raised an additional $12.5 million in a series A round and announced the start of a Phase IIa trial for ATS907 in patients with primary open angle glaucoma and/or...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Company News

Altheos management update

Altheos Inc. , South San Francisco, Calif.   Business: Ophthalmic   Hired: Barbara Wirostko as CMO, formerly senior medical director and glaucoma medical team lead at Pfizer Inc.  ...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Altheos, Asahi Kasei Pharma deal

Asahi Kasei granted Altheos exclusive, worldwide rights, excluding Japan and Korea, to develop and commercialize ATS907 for all indications. ATS907, a Rho kinase inhibitor, is in preclinical development to treat glaucoma. The license also includes...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Altheos board of directors update

Altheos Inc. , South San Francisco, Calif.   Business: Ophthalmic   Appointed: Lester Kaplan, a member of Bay City Capital's scientific advisory board, as chairman; Peter Bisgaard of Novo A/S; Rob Hopfner of Bay City...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Financial News

Altheos completes venture financing

Altheos Inc. , South San Francisco, Calif.   Business: Ophthalmic   Date completed: 4/5/10   Type: Venture financing   Raised: $20 million   Investors: Bay City Capital; Novo A/S; Canaan Partners; Life Science Angels Inc.;...
07:00 , Apr 12, 2010 |  BioCentury  |  Strategy

Altheos Mines its Rho-lodex

After concluding that all the interesting new projects in the U.S. and Europe had been picked over, the founders of Altheos Inc. turned to Asia to find assets for in-licensing. Based on the strength of...
00:56 , Apr 6, 2010 |  BC Extra  |  Financial News

Altheos raises $20M, in-licenses glaucoma compound

Altheos Inc. (South San Francisco, Calif.) raised $20 million in a series A round on Monday and announced a deal with Asahi Kasei Pharma Corp. Asahi granted Altheos exclusive, worldwide rights, excluding Japan and Korea,...